| P50 | author | Gerhard Schembecker | Q83401379 |
| | David Wetzel | Q87174417 |
| | Linda Reiling | Q118533572 |
| | Jack Richards | Q42797472 |
| | Eric Hanssen | Q42996213 |
| | David Anderson | Q45496094 |
| P2093 | author name string | James G Beeson | |
| | Betty Kouskousis | |
| | Jo-Anne Chan | |
| | Andreas Barbian | |
| | Manfred Suckow | |
| | Volker Jenzelewski | |
| | Catherine Palmer | |
| | Juliane Merz | |
| | Michael Piontek | |
| | Michael Weniger | |
| P2860 | cites work | Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria | Q26772878 |
| | New yeast expression platforms based on methylotrophic Hansenula polymorpha and Pichia pastoris and on dimorphic Arxula adeninivorans and Yarrowia lipolytica - a comparison | Q28270864 |
| | A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 |
| | Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli | Q29615261 |
| | Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. | Q30390705 |
| | Crystallization, sequence and preliminary crystallographic data for transmission-blocking anti-malaria Fab 4B7 with cyclic peptides from the Pfs25 protein of P. falciparum | Q30951316 |
| | Methylotrophic yeasts near Ogataea (Hansenula) polymorpha: a proposal of Ogataea angusta comb. nov. and Candida parapolymorpha sp. nov. | Q33584051 |
| | A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies | Q33591209 |
| | St, a truncated envelope protein derived from the S protein of duck hepatitis B virus, acts as a chaperone for the folding of the large envelope protein. | Q33755001 |
| | Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines | Q33812439 |
| | Subviral particle as vaccine and vaccine platform | Q33812653 |
| | Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum | Q34015845 |
| | Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 |
| | CBB staining protocol with higher sensitivity and mass spectrometric compatibility | Q34099297 |
| | Foreign gene expression in yeast: a review | Q34306722 |
| | Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities | Q34340186 |
| | Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization | Q34509612 |
| | A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice | Q35048518 |
| | Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen | Q35123908 |
| | Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex | Q35132063 |
| | N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity | Q35138720 |
| | A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum | Q35138735 |
| | Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. | Q35575993 |
| | Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles | Q35844533 |
| | A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines | Q35874598 |
| | Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates | Q35925379 |
| | Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles | Q36079818 |
| | Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen | Q36228960 |
| | Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum | Q36348052 |
| | Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito | Q36351262 |
| | Human hepatitis B vaccine from recombinant yeast | Q52850114 |
| | Antimalarial Transmission-Blocking Interventions: Past, Present, and Future | Q56339301 |
| | A malaria vaccine adjuvant based on recombinant antigen binding to liposomes | Q57295566 |
| | Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha | Q67980541 |
| | Improved determination of total serum lipids by the sulfo-phospho-vanillin reaction | Q70403772 |
| | Highly-efficient electrotransformation of the yeast Hansenula polymorpha | Q72178965 |
| | Strain and process development for the production of human cytokines in Hansenula polymorpha | Q73288376 |
| | Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination | Q74092600 |
| | Glycosylation of human alpha 1-antitrypsin in Saccharomyces cerevisiae and methylotrophic yeasts | Q74480588 |
| | An expression system matures: a highly efficient and cost-effective process for phytase production by recombinant strains of Hansenula polymorpha | Q74661119 |
| | Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology | Q36442817 |
| | Virus-like particles: passport to immune recognition | Q36602264 |
| | Engineering virus-like particles as vaccine platforms | Q37172342 |
| | Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay | Q37336089 |
| | Virus-like particles in vaccine development. | Q37798008 |
| | Use of baculovirus expression system for generation of virus-like particles: successes and challenges | Q38112493 |
| | Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. | Q38205379 |
| | Toward the development of effective transmission-blocking vaccines for malaria | Q38322553 |
| | Recent developments in malaria vaccinology | Q38441542 |
| | Development of malaria transmission-blocking vaccines: from concept to product | Q38499527 |
| | Naturally acquired immunity to sexual stage P. falciparum parasites. | Q38689928 |
| | Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? | Q38886698 |
| | Production of virus-like particles for vaccines | Q40094178 |
| | Review: methylotrophic yeasts as factories for the production of foreign proteins | Q40960629 |
| | Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis -- a review | Q41499876 |
| | Recombinant Pfs25 protein of plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals | Q42006764 |
| | Re-evaluation of glycerol utilization in Saccharomyces cerevisiae: characterization of an isolate that grows on glycerol without supporting supplements | Q42059253 |
| | A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains | Q43525538 |
| | Isolation and properties of genetically defined strains of the methylotrophic yeast Hansenula polymorpha CBS4732. | Q43864273 |
| | The 230-kDa gamete surface protein of plasmodium falciparum is also a target for transmission-blocking antibodies | Q44146561 |
| | Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials | Q44150427 |
| | Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes | Q44173322 |
| | Anti-Pfs25 monoclonal antibody 32F81 blocks transmission from Plasmodium falciparum gametocyte carriers in Cameroon | Q44173566 |
| | Characterization of N-linked oligosaccharides assembled on secretory recombinant glucose oxidase and cell wall mannoproteins from the methylotrophic yeast Hansenula polymorpha | Q44705090 |
| | Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite | Q47989675 |
| | Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. | Q47998054 |
| | Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose | Q48004480 |
| | Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine | Q48004555 |
| | Establishment of a yeast-based VLP platform for antigen presentation. | Q48103866 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| | malaria | Q12156 |
| | Hansenula polymorpha | Q80864459 |
| P304 | page(s) | e0221394 | |
| P577 | publication date | 2019-09-04 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha | |
| P478 | volume | 14 | |